Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
605 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Multiple Sclerosis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Multiple Sclerosis - Pipeline Review, H2 2014', provides an overview of the Multiple Sclerosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Multiple Sclerosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Multiple Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 8 Multiple Sclerosis Overview 9 Therapeutics Development 10 Multiple Sclerosis - Therapeutics under Development by Companies 12 Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes 25 Multiple Sclerosis - Pipeline Products Glance 28 Multiple Sclerosis - Products under Development by Companies 32 Multiple Sclerosis - Products under Investigation by Universities/Institutes 45 Multiple Sclerosis - Companies Involved in Therapeutics Development 48 Multiple Sclerosis - Therapeutics Assessment 185 Drug Profiles 204 Multiple Sclerosis - Recent Pipeline Updates 501 Multiple Sclerosis - Dormant Projects 565 Multiple Sclerosis - Discontinued Products 568 Multiple Sclerosis - Product Development Milestones 569 Appendix 578
List of Tables Number of Products under Development for Multiple Sclerosis, H2 2014 36 Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H2 2014 37 Number of Products under Development by Companies, H2 2014 39 Number of Products under Development by Companies, H2 2014 (Contd..1) 40 Number of Products under Development by Companies, H2 2014 (Contd..2) 41 Number of Products under Development by Companies, H2 2014 (Contd..3) 42 Number of Products under Development by Companies, H2 2014 (Contd..4) 43 Number of Products under Development by Companies, H2 2014 (Contd..5) 44 Number of Products under Development by Companies, H2 2014 (Contd..6) 45 Number of Products under Development by Companies, H2 2014 (Contd..7) 46 Number of Products under Development by Companies, H2 2014 (Contd..8) 47 Number of Products under Development by Companies, H2 2014 (Contd..9) 48 Number of Products under Development by Companies, H2 2014 (Contd..10) 49 Number of Products under Development by Companies, H2 2014 (Contd..11) 50 Number of Products under Investigation by Universities/Institutes, H2 2014 52 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 53 Comparative Analysis by Late Stage Development, H2 2014 54 Comparative Analysis by Clinical Stage Development, H2 2014 55 Comparative Analysis by Early Stage Development, H2 2014 56 Comparative Analysis by Unknown Stage Development, H2 2014 57 Products under Development by Companies, H2 2014 58 Products under Development by Companies, H2 2014 (Contd..1) 59 Products under Development by Companies, H2 2014 (Contd..2) 60 Products under Development by Companies, H2 2014 (Contd..3) 61 Products under Development by Companies, H2 2014 (Contd..4) 62 Products under Development by Companies, H2 2014 (Contd..5) 63 Products under Development by Companies, H2 2014 (Contd..6) 64 Products under Development by Companies, H2 2014 (Contd..7) 65 Products under Development by Companies, H2 2014 (Contd..8) 66 Products under Development by Companies, H2 2014 (Contd..9) 67 Products under Development by Companies, H2 2014 (Contd..10) 68 Products under Development by Companies, H2 2014 (Contd..11) 69 Products under Development by Companies, H2 2014 (Contd..12) 70 Products under Investigation by Universities/Institutes, H2 2014 71 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 72 Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 73 Multiple Sclerosis - Pipeline by Genzyme Corporation, H2 2014 74 Multiple Sclerosis - Pipeline by Biogen Idec Inc., H2 2014 75 Multiple Sclerosis - Pipeline by Advanced Cell Technology, Inc., H2 2014 76 Multiple Sclerosis - Pipeline by Athersys, Inc., H2 2014 77 Multiple Sclerosis - Pipeline by GlaxoSmithKline plc, H2 2014 78 Multiple Sclerosis - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 79 Multiple Sclerosis - Pipeline by MedImmune, LLC, H2 2014 80 Multiple Sclerosis - Pipeline by Biotest AG, H2 2014 81 Multiple Sclerosis - Pipeline by Alkermes Plc, H2 2014 82 Multiple Sclerosis - Pipeline by Plexxikon Inc., H2 2014 83 Multiple Sclerosis - Pipeline by Apitope International NV, H2 2014 84 Multiple Sclerosis - Pipeline by Hanwha Chemical Co., Ltd., H2 2014 85 Multiple Sclerosis - Pipeline by Aphios Corporation, H2 2014 86 Multiple Sclerosis - Pipeline by Acorda Therapeutics, Inc., H2 2014 87 Multiple Sclerosis - Pipeline by Biocon Limited, H2 2014 88 Multiple Sclerosis - Pipeline by Eisai Co., Ltd., H2 2014 89 Multiple Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 90 Multiple Sclerosis - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 91 Multiple Sclerosis - Pipeline by Pfizer Inc., H2 2014 92 Multiple Sclerosis - Pipeline by Rigel Pharmaceuticals, Inc., H2 2014 93 Multiple Sclerosis - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2014 94 Multiple Sclerosis - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 95 Multiple Sclerosis - Pipeline by Paratek Pharmaceuticals, Inc., H2 2014 96 Multiple Sclerosis - Pipeline by OPKO Health, Inc., H2 2014 97 Multiple Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2014 98 Multiple Sclerosis - Pipeline by Merck KGaA, H2 2014 99 Multiple Sclerosis - Pipeline by 4SC AG, H2 2014 100 Multiple Sclerosis - Pipeline by Addex Therapeutics Ltd, H2 2014 101 Multiple Sclerosis - Pipeline by Evotec AG, H2 2014 102 Multiple Sclerosis - Pipeline by Harbor Therapeutics, Inc., H2 2014 103 Multiple Sclerosis - Pipeline by Neuralstem, Inc., H2 2014 104 Multiple Sclerosis - Pipeline by Idera Pharmaceuticals, Inc., H2 2014 105 Multiple Sclerosis - Pipeline by Karo Bio AB, H2 2014 106 Multiple Sclerosis - Pipeline by Almirall, S.A., H2 2014 107 Multiple Sclerosis - Pipeline by Lpath, Inc., H2 2014 108 Multiple Sclerosis - Pipeline by Bionomics Limited, H2 2014 109 Multiple Sclerosis - Pipeline by MultiCell Technologies, Inc., H2 2014 110 Multiple Sclerosis - Pipeline by Neuren Pharmaceuticals Limited, H2 2014 111 Multiple Sclerosis - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2014 112 Multiple Sclerosis - Pipeline by Compugen Ltd., H2 2014 113 Multiple Sclerosis - Pipeline by Critical Outcome Technologies Inc., H2 2014 114 Multiple Sclerosis - Pipeline by Acadia Pharmaceuticals Inc., H2 2014 115 Multiple Sclerosis - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2014 116 Multiple Sclerosis - Pipeline by NeoStem, Inc., H2 2014 117 Multiple Sclerosis - Pipeline by Array BioPharma Inc., H2 2014 118 Multiple Sclerosis - Pipeline by Xenetic Biosciences plc, H2 2014 119 Multiple Sclerosis - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 120 Multiple Sclerosis - Pipeline by LG Life Sciences, Ltd., H2 2014 121 Multiple Sclerosis - Pipeline by Pluristem Therapeutics Inc., H2 2014 122 Multiple Sclerosis - Pipeline by Resverlogix Corp., H2 2014 123 Multiple Sclerosis - Pipeline by Sareum Holdings plc, H2 2014 124 Multiple Sclerosis - Pipeline by InDex Pharmaceuticals AB, H2 2014 125 Multiple Sclerosis - Pipeline by Morphotek, Inc., H2 2014 126 Multiple Sclerosis - Pipeline by Digna Biotech, S.L., H2 2014 127 Multiple Sclerosis - Pipeline by Antipodean Pharmaceuticals, Inc., H2 2014 128 Multiple Sclerosis - Pipeline by Antitope Ltd., H2 2014 129 Multiple Sclerosis - Pipeline by Axxam SpA, H2 2014 130 Multiple Sclerosis - Pipeline by Pieris AG, H2 2014 131 Multiple Sclerosis - Pipeline by Hutchison MediPharma Limited, H2 2014 132 Multiple Sclerosis - Pipeline by Argos Therapeutics, Inc., H2 2014 133 Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H2 2014 134 Multiple Sclerosis - Pipeline by Coronado Biosciences, Inc., H2 2014 135 Multiple Sclerosis - Pipeline by MacroGenics, Inc., H2 2014 136 Multiple Sclerosis - Pipeline by Q Therapeutics, Inc., H2 2014 137 Multiple Sclerosis - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2014 138 Multiple Sclerosis - Pipeline by Vaccinex, Inc., H2 2014 139 Multiple Sclerosis - Pipeline by Kineta, Inc., H2 2014 140 Multiple Sclerosis - Pipeline by MSM Protein Technologies, Inc., H2 2014 141 Multiple Sclerosis - Pipeline by Vascular Biogenics Ltd., H2 2014 142 Multiple Sclerosis - Pipeline by Endocyte, Inc., H2 2014 143 Multiple Sclerosis - Pipeline by Theraclone Sciences, Inc., H2 2014 144 Multiple Sclerosis - Pipeline by Effimune SAS, H2 2014 145 Multiple Sclerosis - Pipeline by InteKrin Therapeutics, Inc., H2 2014 146 Multiple Sclerosis - Pipeline by Siena Biotech S.p.A., H2 2014 147 Multiple Sclerosis - Pipeline by Virogenomics, Inc., H2 2014 148 Multiple Sclerosis - Pipeline by Omeros Corporation, H2 2014 149 Multiple Sclerosis - Pipeline by Bolder Biotechnology, Inc., H2 2014 150 Multiple Sclerosis - Pipeline by Aegis Therapeutics, LLC, H2 2014 151 Multiple Sclerosis - Pipeline by Dimerix Bioscience Pty Ltd, H2 2014 152 Multiple Sclerosis - Pipeline by Cellceutix Corporation, H2 2014 153 Multiple Sclerosis - Pipeline by Biovista Inc., H2 2014 154 Multiple Sclerosis - Pipeline by Invion Limited, H2 2014 155 Multiple Sclerosis - Pipeline by SanBio, Inc., H2 2014 156 Multiple Sclerosis - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2014 157 Multiple Sclerosis - Pipeline by Provid Pharmaceuticals, Inc., H2 2014 158 Multiple Sclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2014 159 Multiple Sclerosis - Pipeline by Biokine Therapeutics Ltd., H2 2014 160 Multiple Sclerosis - Pipeline by OncoImmune, Inc., H2 2014 161 Multiple Sclerosis - Pipeline by to-BBB technologies BV, H2 2014 162 Multiple Sclerosis - Pipeline by KAHR medical Ltd., H2 2014 163 Multiple Sclerosis - Pipeline by Lycera Corp., H2 2014 164 Multiple Sclerosis - Pipeline by MAKScientific, LLC, H2 2014 165 Multiple Sclerosis - Pipeline by RhinoCyte, Inc., H2 2014 166 Multiple Sclerosis - Pipeline by Vakzine Projekt Management GmbH, H2 2014 167 Multiple Sclerosis - Pipeline by KAEL-GemVax Co., Ltd., H2 2014 168 Multiple Sclerosis - Pipeline by Pfenex Inc., H2 2014 169 Multiple Sclerosis - Pipeline by Vicore Pharma AB, H2 2014 170 Multiple Sclerosis - Pipeline by Cellmid Limited, H2 2014 171 Multiple Sclerosis - Pipeline by Synthon BV, H2 2014 172 Multiple Sclerosis - Pipeline by Varinel, Inc., H2 2014 173 Multiple Sclerosis - Pipeline by Cognosci, Inc., H2 2014 174 Multiple Sclerosis - Pipeline by Immune Technologies and Medicine, H2 2014 175 Multiple Sclerosis - Pipeline by Targazyme, Inc., H2 2014 176 Multiple Sclerosis - Pipeline by ProNoxis AB, H2 2014 177 Multiple Sclerosis - Pipeline by Cell Cure Neurosciences, Ltd., H2 2014 178 Multiple Sclerosis - Pipeline by GeNeuro SA, H2 2014 179 Multiple Sclerosis - Pipeline by VivaCell Biotechnology Espana S.L., H2 2014 180 Multiple Sclerosis - Pipeline by Forward Pharma A/S, H2 2014 181 Multiple Sclerosis - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2014 182 Multiple Sclerosis - Pipeline by Regenesance BV, H2 2014 183 Multiple Sclerosis - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 184 Multiple Sclerosis - Pipeline by Kareus Therapeutics, SA, H2 2014 185 Multiple Sclerosis - Pipeline by Lead Discovery Center GmbH, H2 2014 186 Multiple Sclerosis - Pipeline by BRAINco Biopharma, S.L., H2 2014 187 Multiple Sclerosis - Pipeline by Immunaffect B.V., H2 2014 188 Multiple Sclerosis - Pipeline by SOM Biotech SL, H2 2014 189 Multiple Sclerosis - Pipeline by Immune Response BioPharma, Inc., H2 2014 190 Multiple Sclerosis - Pipeline by Bionure Farma, S.L., H2 2014 191 Multiple Sclerosis - Pipeline by IntelliCell BioSciences Inc., H2 2014 192 Multiple Sclerosis - Pipeline by The International Biotechnology Center (IBC) �Generium�, H2 2014 193 Multiple Sclerosis - Pipeline by Arrien Pharmaceuticals, LLC, H2 2014 194 Multiple Sclerosis - Pipeline by Creabilis SA, H2 2014 195 Multiple Sclerosis - Pipeline by CalAsia Pharmaceuticals, Inc., H2 2014 196 Multiple Sclerosis - Pipeline by Evgen Limited, H2 2014 197 Multiple Sclerosis - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 198 Multiple Sclerosis - Pipeline by Io Therapeutics, Inc., H2 2014 199 Multiple Sclerosis - Pipeline by Lanthio Pharma B.V., H2 2014 200 Multiple Sclerosis - Pipeline by ReveraGen BioPharma, Inc., H2 2014 201 Multiple Sclerosis - Pipeline by Endece, LLC, H2 2014 202 Multiple Sclerosis - Pipeline by Biomar Microbial Technologies, H2 2014 203 Multiple Sclerosis - Pipeline by GliaCure Inc., H2 2014 204 Multiple Sclerosis - Pipeline by ImmuNext, Inc., H2 2014 205 Multiple Sclerosis - Pipeline by Toleranzia AB, H2 2014 206 Multiple Sclerosis - Pipeline by Mapi Pharma Ltd., H2 2014 207 Multiple Sclerosis - Pipeline by Glialogix, Inc., H2 2014 208 Multiple Sclerosis - Pipeline by Bionature E.A. Ltd., H2 2014 209 Multiple Sclerosis - Pipeline by Dong-A Socio Group, H2 2014 210 Assessment by Monotherapy Products, H2 2014 211 Assessment by Combination Products, H2 2014 212 Number of Products by Stage and Target, H2 2014 215 Number of Products by Stage and Mechanism of Action, H2 2014 221 Number of Products by Stage and Route of Administration, H2 2014 226 Number of Products by Stage and Molecule Type, H2 2014 229 Multiple Sclerosis Therapeutics - Recent Pipeline Updates, H2 2014 527 Multiple Sclerosis - Dormant Projects, H2 2014 591 Multiple Sclerosis - Discontinued Products, H2 2014 594
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
